Zilico, which are part of the Deepbridge Life Sciences EIS portfolio, have been selected to be a part of the inaugural Digital North Accelerator Programme, facilitating adoption and spread of innovation.

The programme is set by the Academic Health Science Networks (AHSNs) to provide support to SMEs across the UK to increase reach and adoption of innovation in the north of England.  

This programme will guide each company with new introductions to NHS customers across four regions of the north, and also provide guidance to demonstrate the impact and benefit that the SME's have on patients, for example Zilico's Electrical Impedance Spectroscopy (EIS) cancer diagnostic device technology. 

Among Zilico, IEG4, Doc Abode, Bruin Biometrics and Cievert have also been chosen for the programme. 

To read more, click here. 

About Zilico

Zilico Ltd has developed an innovative cancer diagnostic device technology that employs Electrical Impedance Spectroscopy (‘EIS’) within a device that seeks to improve and extend current cancer screening programmes, by providing accurate and objective results in real-time. The initial focus of the Company is to address the detection of cervical cancer and oral cancer, and the Company plans to apply the same approach to oesophageal, anal, vaginal and vulva cancers.